Gilead raises outlook despite dip in revenue
admin 25th October 2018 Uncategorised 0Total revenues were $5.6 billion in 2018 compared to $6.5 billion in 2017 More: Gilead raises outlook despite dip in revenue Source: News
read more
Total revenues were $5.6 billion in 2018 compared to $6.5 billion in 2017 More: Gilead raises outlook despite dip in revenue Source: News
read moreThe drug was one of the company’s few original experimental drugs close to reaching the market More: Lundbeck schizophrenia drug fails Phase III trial Source: News
read moreIt’s no secret that Bristol-Myers Squibb’s investors are feeling skittish after a pair of negative Opdivo developments last week. And on Thursday’s third-quarter conference call, executives plunged right into their doubts. More: Opdivo will keep growing, Bristol-Myers says, trying to
read moreMerck & Co. has a jet engine for growth in its oncology star Keytruda, but long-term it needs more than cancer to keep growth coming. How, then, to diversify? Dealmaking, for one thing, CEO Ken Frazier said Thursday, but he
read moreThe new PharmaTimes Medical and Scientific Excellence Awards, designed to recognise the outstanding achievements of medical and scientific professionals will close for entry on the 31st October. More: Medical and Scientific Excellence Awards: There's still time to enter! Source: News
read moreAbbVie has decided to take over Galapagos’ entire cystic fibrosis portfolio, instead of collaborating, adding heft to its competitive bid. But Vertex CEO Jeffrey Leiden said his company’s drugs have raised the efficacy bar so high, even a pharma giant
read more© 1994 - 2025 B.M. Pharmaceuticals